Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
, 109 (3), 351-355

Neutropenic Enterocolitis in Patients With FLT3 Mutated Acute Myeloid Leukemia Undergoing Induction Chemotherapy With Midostaurin

Affiliations
Case Reports

Neutropenic Enterocolitis in Patients With FLT3 Mutated Acute Myeloid Leukemia Undergoing Induction Chemotherapy With Midostaurin

Jennifer Dotson et al. Int J Hematol.

Abstract

Neutropenic enterocolitis mostly affects patients with acute myeloid leukemia (AML) who get treated with intensive chemotherapy which is associated with prolonged neutropenia; its pathogenesis is not well understood and the main factors in this life-threatening condition appear to be neutropenia, mucosal injury and a weakened immune system as a consequence of intensive chemotherapeutic agents. Midostaurin in combination with chemotherapy became the standard of care for FLT3 mutant AML since its approval by the United States Food and Drug Administration (FDA) in April 2017. Anecdotally in our institution, we noticed the common occurrence of neutropenic colitis in three out of three patients who were treated with midostaurin as part of induction chemotherapy for AML.

Keywords: AML; Midostaurin; Neutropenic enterocolitis.

Similar articles

See all similar articles

References

    1. Can J Surg. 1999 Dec;42(6):415-9 - PubMed
    1. Cancer Invest. 2001;19(7):669-77 - PubMed
    1. Blood. 2002 Jun 15;99(12):4326-35 - PubMed
    1. Eur J Haematol. 2005 Jul;75(1):1-13 - PubMed
    1. Cancer. 1990 Feb 15;65(4):1041-7 - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback